University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven

PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system (2022) Gui X, Bazarova A, Del Amor R, De Hertogh G, Villanacci V, Zardo D, Parigi TL, et al. Journal article Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies (2022) Cavagna L, Meloni F, Meyer A, Sambataro G, Belliato M, De Langhe E, Cavazzana I, et al. Journal article Rare germline copy number variants (CNVs) and breast cancer risk (2022) Dennis J, Tyrer JP, Walker LC, Michailidou K, Dorling L, Bolla MK, Wang Q, et al. Journal article Common variants in breast cancer risk loci predispose to distinct tumor subtypes (2022) Ahearn TU, Zhang H, Michailidou K, Milne RL, Bolla MK, Dennis J, Dunning AM, et al. Journal article Hybrid APC in Combination With Resection for the Endoscopic Treatment of Neoplastic Barrett's Esophagus: A Prospective, Multicenter Study (2022) Knabe M, Beyna T, Rösch T, Bergman J, Manner H, May A, Schachschal G, et al. Journal article Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’: (Annals of Oncology (2021) 32(3) (309–322), (S0923753420431692), (10.1016/j.annonc.2020.11.014)) (2022) Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, et al. Journal article, Erratum Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies. (2022) Cavagna L, Meloni F, Meyer A, Sambataro G, Belliato M, De Langhe E, Cavazzana I, et al. Journal article Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial (2022) Sandborn WJ, Panés J, Danese S, Sharafali Z, Hassanali A, Jacob-Moffatt R, Eden C, et al. Journal article The serotonin receptor 3E variant is a risk factor for female IBS-D (2022) Fritz N, Berens S, Dong Y, Martínez C, Schmitteckert S, Houghton LA, Goebel-Stengel M, et al. Journal article CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease (2022) Ma C, Hanzel J, Panaccione R, Sandborn WJ, D'Haens GR, Ahuja V, Atreya R, et al. Journal article